Cara Therapeutics, Inc. Form SC 13G/A February 13, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Cara Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

140755109

(CUSIP Number)

December 31, 2014

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
- x Rule 13d-1(c)
- o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 2 of 12

Schedule 13G

CUSIP No. 140755109

PN

NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 1 Ascent Biomedical Ventures I, L.P. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 2 (a) o (b) x SEC USE ONLY 3 CITIZENSHIP OR PLACE OF ORGANIZATION 4 Delaware **SOLE VOTING POWER** 5 NUMBER OF Not applicable **SHARES** SHARED VOTING POWER **BENEFICIALLY** 6 **OWNED BY** 963,896 **EACH** REPORTING SOLE DISPOSITIVE POWER **PERSON** 7 WITH Not applicable SHARED DISPOSITIVE POWER 8 963,896 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9 963,896 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES x(1)**CERTAIN SHARES (See Instructions)** 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 4.2% TYPE OF REPORTING PERSON (See Instructions) 12

Edgar Filing: Cara Therapeutics, In	Inc Form S	3C 13G/A
-------------------------------------	------------	----------

(1) See footnote to Item 4 herein.

Page 3 of 12

Schedule 13G

CUSIP No. 140755109

NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 1 Ascent Biomedical Ventures I Annex, L.P. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 2 (a) o (b) x SEC USE ONLY 3 CITIZENSHIP OR PLACE OF ORGANIZATION 4 Delaware **SOLE VOTING POWER** 5 NUMBER OF Not applicable **SHARES** SHARED VOTING POWER **BENEFICIALLY** 6 **OWNED BY** 131,169 **EACH REPORTING** SOLE DISPOSITIVE POWER **PERSON** 7 WITH Not applicable SHARED DISPOSITIVE POWER 8 131,169 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9 131,169 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES x(2)**CERTAIN SHARES (See Instructions)** 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 0.6% TYPE OF REPORTING PERSON (See Instructions) 12 PN

(2) See footnote to Item 4 herein.

Page 4 of 12

Schedule 13G

CUSIP No. 140755109

PN

NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 1 Ascent Biomedical Ventures I NY, L.P. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 2 (a) o (b) x SEC USE ONLY 3 CITIZENSHIP OR PLACE OF ORGANIZATION 4 Delaware SOLE VOTING POWER 5 NUMBER OF Not applicable **SHARES** SHARED VOTING POWER **BENEFICIALLY** 6 **OWNED BY** 604,428 **EACH REPORTING** SOLE DISPOSITIVE POWER **PERSON** 7 WITH Not applicable SHARED DISPOSITIVE POWER 8 604,428 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9 604,428 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES x(3)**CERTAIN SHARES (See Instructions)** 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 2.7% TYPE OF REPORTING PERSON (See Instructions) 12

(3) See footnote to Item 4 herein.

Page 5 of 12

Schedule 13G

CUSIP No. 140755109

OO

NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 1 ABV, LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 2 (a) o (b) x SEC USE ONLY 3 CITIZENSHIP OR PLACE OF ORGANIZATION 4 Delaware **SOLE VOTING POWER** 5 NUMBER OF Not applicable **SHARES** SHARED VOTING POWER BENEFICIALLY 6 **OWNED BY** 1,699,493 (4) **EACH** REPORTING SOLE DISPOSITIVE POWER **PERSON** 7 WITH Not applicable SHARED DISPOSITIVE POWER 8 1,699,493 (4) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9 1,699,493 (4) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES x(5)**CERTAIN SHARES (See Instructions)** 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 7.5% TYPE OF REPORTING PERSON (See Instructions) 12

- (4) Comprised of shares of common stock held by Ascent Biomedical Ventures I, L.P., Ascent Biomedical Ventures I Annex, L.P. and Ascent Biomedical Ventures I NY, L.P, of which ABV, LLC is the general partner.
- (5) See footnote to Item 4 herein.

Page 6 of 12

Schedule 13G

CUSIP No. 140755109

IN

NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 1 Geoffrey W. Smith CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 2 (a) o (b) x SEC USE ONLY 3 CITIZENSHIP OR PLACE OF ORGANIZATION 4 **United States SOLE VOTING POWER** 5 NUMBER OF Not applicable **SHARES** SHARED VOTING POWER **BENEFICIALLY** 6 **OWNED BY** 1,699,493 (6) **EACH** SOLE DISPOSITIVE POWER **REPORTING PERSON** 7 WITH Not applicable SHARED DISPOSITIVE POWER 8 1,699,493 (6) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9 1,699,493 (6) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES x(7)**CERTAIN SHARES (See Instructions)** 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 7.5% TYPE OF REPORTING PERSON (See Instructions) 12

- (6) Comprised of shares of common stock held by Ascent Biomedical Ventures I, L.P., Ascent Biomedical Ventures I Annex, L.P. and Ascent Biomedical Ventures I NY, L.P.
- (7) See footnote to Item 4 herein.

Page 7 of 12

Schedule 13G

CUSIP No. 140755109

IN

NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 1 Steve Hochberg CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 2 (a) o (b) x SEC USE ONLY 3 CITIZENSHIP OR PLACE OF ORGANIZATION 4 **United States SOLE VOTING POWER** 5 NUMBER OF Not applicable **SHARES** SHARED VOTING POWER **BENEFICIALLY** 6 **OWNED BY** 1,699,493 (8) **EACH** SOLE DISPOSITIVE POWER **REPORTING PERSON** 7 WITH Not applicable SHARED DISPOSITIVE POWER 8 1,699,493 (8) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9 1,699,493 (8) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES x(9)**CERTAIN SHARES (See Instructions)** 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 7.5% TYPE OF REPORTING PERSON (See Instructions) 12

- (8) Comprised of shares of common stock held by Ascent Biomedical Ventures I, L.P., Ascent Biomedical Ventures I Annex, L.P. and Ascent Biomedical Ventures I NY, L.P.
- (9) See footnote to Item 4 herein.

CUSIP No. 140755109 Page 8 of 12 Item 1. (a) Name of Issuer: Cara Therapeutics, Inc. Address of Issuer's Principal Executive Offices: (b) 1 Parrott Drive, Shelton, Connecticut 06484 Item 2. (a) Name of Person Filing: (i) Ascent Biomedical Ventures I, L.P. ("Ascent") (ii) Ascent Biomedical Ventures I Annex, L.P. ("Ascent Annex") (iii) Ascent Biomedical Ventures I NY, L.P. ("Ascent NY") ABV, LLC ("ABV") (iv) (v) Geoffrey W. Smith ("Geoffrey Smith") (vi) Steve Hochberg ("Steve Hochberg" and together with Ascent, Ascent Annex, Ascent NY, ABV, and Geoffrey Smith, the "Reporting Persons") (b) Address of Principal Business Office or, if none, Residence: 142 West 57th Street, 4A, New York, NY 10019 (i) 142 West 57th Street, 4A, New York, NY 10019 (ii) (iii) 142 West 57th Street, 4A, New York, NY 10019 142 West 57th Street, 4A, New York, NY 10019 (iv) (v) 142 West 57th Street, 4A, New York, NY 10019 142 West 57th Street, 4A, New York, NY 10019 (vi) Citizenship: (c) Delaware limited liability partnership (i)

(ii)

Delaware limited liability partnership

(iii)	Delaware limited liability partnership
(iv)	Delaware limited liability company
(v)	United States Citizen
(vi)	United States Citizen

CUSIP No. 140755109	Page 9 of 12
(d)	Title of Class of Securities:
Common Stock	
(e)	CUSIP Number:
140755109	
Item 3.	
Not applicable.	
Item 4. Ownership.	
(a)	Amount Beneficially Owned**:
The responses of the Reporting herein by reference.	Persons to Rows (9) through (10) of the cover pages of this Statement are incorporated
(b)	Percent of Class**:
The responses of the Reporting reference.	Persons to Row (11) of the cover pages of this Statement are incorporated herein by
(c)	Number of shares as to which the person has**:
The responses of the Reporting herein by reference.	Persons to Rows (5) through (8) of the cover pages of this Statement are incorporated
ABV is the general partner of A Steve Hochberg.	scent, Ascent Annex and Ascent NY. The directors of ABV are Geoffrey Smith and
an aggregate of 473,588 shares hereto, which individuals and e purposes of Section 13(d)(3) undisclaim beneficial ownership of	which are incorporated by reference herein. The shares reported herein do not include of common stock of the Issuer held by the individuals and entities listed on Exhibit B natities are not reporting persons hereunder but may be deemed to constitute a group for der the Exchange Act of 1934, with the Reporting Persons. The Reporting Persons were the shares held by the individuals and entities listed on Exhibit B hereunder and p with such individuals and entities.
Item 5. Ownership of Five Pero	eent or Less of a Class.
Not applicable.	
Item 6. Ownership of More tha	n Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
Not applicable.

CUSIP No. 140755109 Page 10 of 12

Item 8. Identification and Classification of Member of the Group.

See Exhibit B.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11.

Material to be Filed as Exhibits.

Exhibit A: Joint Filing Agreement

Exhibit B: Item 8 Statement

CUSIP No. 140755109 Page 11 of 12

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 13, 2015

ASCENT BIOMEDICAL VENTURES I, L.P.

By: ABV, LLC

its general partner

/s/ Steve Hochberg

Signature

Director

Name/Title

ASCENT BIOMEDICAL VENTURES I ANNEX, L.P.

By: ABV, LLC

its general partner1

/s/ Steve Hochberg

Signature

Director

Name/Title

ASCENT BIOMEDICAL VENTURES I NY, L.P.

By: ABV, LLC

its general partner1

/s/ Steve Hochberg

Signature

Director

Name/Title

ABV, LLC

/s/ Steve Hochberg Signature

Director Name/Title CUSIP No. 140755109 Page 12 of 12

GEOFFREY W. SMITH1

/s/ Geoffrey W. Smith Signature

STEVE HOCHBERG1

/s/ Steve Hochberg Signature